Amgen Canada Inc., in consultation with Health Canada, would like to inform you of important new safety information concerning the risk of Capillary Leak Syndrome (CLS) associated with the granulocyte colony stimulating factors (G-CSF) NEUPOGEN and NEULASTA. Cases of Capillary Leak Syndrome (CLS) have been reported in:
a. patients undergoing chemotherapy who were receiving NEUPOGEN or NEULASTA, and
b. donors undergoing peripheral blood progenitor cell mobilization who were receiving NEUPOGEN.
Read more here.
No comments:
Post a Comment